Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era

Sodium-glucose cotransporter 2 inhibitors could reduce cardiovascular mortality and adverse kidney events in patients with cardiovascular-kidney-metabolic syndrome.

• CKM syndrome involves a complex relationship among obesity, hypertension, type 2 diabetes, chronic kidney disease, and cardiovascular disease.
• Sodium-glucose cotransporter 2 inhibitors may lead to fewer hospitalizations for heart failure across various patient groups, regardless of diabetes status.
• Glucagon-like peptide-1 receptor agonists could provide significant benefits in weight loss and glycemic control, as well as lower cardiovascular and kidney-related events.
• There is a need for equitable access to these medications to ensure high-risk populations receive necessary treatment.
• Future efforts should focus on developing precision-based therapeutic strategies and policies to improve CKM syndrome management.

AI simplified